In a research facility outside of Auckland that resembles an agricultural office rather than a pharmaceutical lab, scientists have been working in secret for years on a project that the global weight-loss industry probably wishes had remained hidden in a hop field. The compound is known as Amarasate, and its concept is nearly unyieldingly straightforward. One of the body’s earliest appetite control switches may be the bitter taste that most people automatically spit out. It is now known as the bitter brake because it is located deep within the stomach rather than on the tongue.
For something so physiological, it’s an odd phrase. However, the name makes sense once you realize what’s going on. Before deciding on a concentrated hop derivative that produced a detectable reaction in enteroendocrine cells—those tiny, unseen hormone factories dispersed throughout the intestinal lining—researchers screened over 900 plant extracts. They release GLP-1, PYY, and CCK when activated, which are the same satiety hormones that pharmaceutical companies have spent billions attempting to replicate with injectables.
| Key Information | Details |
|---|---|
| Compound Name | Amarasate™ Extract |
| Source Plant | Humulus lupulus (Hops) |
| Country of Origin | New Zealand |
| Developer | Plant & Food Research Limited, University of Auckland |
| Lead Researcher | Dr. John Ingram |
| Mechanism | Activation of TAS2R bitter taste receptors in the gut |
| Hormones Triggered | GLP-1, PYY, and CCK |
| Typical Clinical Dose | 125 mg to 500 mg before meals |
| Calorie Reduction Observed | Roughly 218–226 calories per meal cycle |
| Safety Status | GRAS-recognized by the U.S. FDA |
| Common Side Effects | Mild diarrhea, occasional heartburn |
| First Major Trial Year | 2016 (European Obesity Summit, Gothenburg) |
That has a subtle irony to it. A bitter plant extract from New Zealand seems to hint that the body may already know how to do some of this on its own, while Ozempic and its cousins dominate headlines, prescription pads, and celebrity gossip columns. Naturally, less dramatically. less profitable as well. In pharmaceutical economics, growth in a field is typically not favored.
Even though the clinical results are modest, they are hard to ignore. Amarasate gastric or duodenal-release capsules were administered to twenty lean men prior to lunch in one study. The participants consumed between 218 and 226 fewer calories during the remainder of the day, indicating that the food intake reductions were not hypothetical. They didn’t even say they were less hungry. Simply put, their bodies ceased to demand more. The part that sticks with you is that detail, which was practically a footnote in the original paper.
Since then, researchers have expanded into studies involving female participants, fasting regimens, and different dosage schedules. In their 2024 study, Walker and colleagues found that female participants’ post-fast energy intake decreased by almost 14%. It’s not too late yet. The populations are small, the trials are brief, and the long-term picture is largely blank. The scientists involved, however, feel that they have discovered a mechanism that textbooks have downplayed for decades.
The cultural timing is difficult to ignore. A non-prescription, plant-derived substance that activates the same hormonal pathway feels almost subversive as semaglutide shortages spread through pharmacies and patients discuss the morality of off-label use. Although there isn’t a direct threat to Big Pharma just yet, the bitter brake raises concerns for a sector that relies on synthesizing natural resources.
It’s still genuinely unclear if Amarasate will become a common supplement, a functional food ingredient, or a footnote in the history of nutrition. Though not definitive, the science is encouraging. The trials are encouraging but not conclusive. However, it seems like the gut has been trying to tell us something for a very long time when you sit with the data and observe the gradual accumulation of tiny, consistent findings. We simply weren’t paying attention to the negative aspects.
